|
Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model |
Pufulete M, Maishman R, Dabner L, Mohiuddin S, Hollingworth W, Rogers C A, Higgins J, Dayer M, Macleod J, Purdy S, McDonagh T, Nightingale A, Williams R & Reeves B C |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pufulete M, Maishman R, Dabner L, Mohiuddin S, Hollingworth W, Rogers C A, Higgins J, Dayer M, Macleod J, Purdy S, McDonagh T, Nightingale A, Williams R & Reeves B C. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model. Health Technology Assessment 2017; 21(40) Authors' objectives To evaluate the clinical effectiveness and cost-effectiveness of B-type natriuretic peptide (BNP)-guided therapy compared with symptom-guided therapy in heart failure (HF) patients.
Authors' conclusions The efficacy of BNP-guided therapy in specialist HF clinics is uncertain. If efficacious, it would be cost-effective for patients aged < 75 years with HFrEF. The evidence reviewed may not apply in the UK because care is delivered differently. Indexing Status Subject indexing assigned by CRD MeSH Heart Failure; Humans; Natriuretic Peptide, Brain; Primary Health Care; Secondary Prevention Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber 32013000961 Date abstract record published 16/12/2013 |
|
|
|